Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory N...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatnagar, Amelia, Boyd, Sandra, Sabour, Sarah, Bodnar, Janine, Nazarian, Elizabeth, Peinovich, Nadine, Wagner, Christine, Craft, Bradley, Snippes Vagnone, Paula, Simpson, Justin, Stone, Victoria N., Therrien, Michelle, Bateman, Allen, Lower, Danielle, Huang, Jennifer Y., Gumbis, Stephanie, Lonsway, David, Lutgring, Joseph D., Karlsson, Maria, Brown, Allison C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284474/
https://www.ncbi.nlm.nih.gov/pubmed/34060895
http://dx.doi.org/10.1128/AAC.00486-21
Descripción
Sumario:Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC(50) and MIC(90) values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested.

Ejemplares similares